ArticleEuropean journal of clinical pharmacology2009
Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis.
Article in European journal of clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04867135 (Population Pharmacokinetics of Amikacin in Suspected Cases of Neonatal Sepsis), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Population Pharmacokinetics of Amikacin in Suspected Cases of Neonatal Sepsis: Multicenter Study
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates.The Indian journal of medical research · 2017Pooled it
- Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.British journal of clinical pharmacology · 2016Trial
- Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants.The Pediatric infectious disease journal · 2013Trial
- Population Pharmacokinetics of Amikacin in Non-Neonatal Pediatric Patients: A Scoping Review.European journal of drug metabolism and pharmacokinetics · 2026Article
- Amikacin toxicity revisited: pentoxifylline offers protection in high-risk treatment scenarios.AMB Express · 2025Article
- Precision dosing of amikacin in term neonates using pharmacometric approach.Pediatric research · 2025Article
- Externally validated population pharmacokinetics of amikacin and evaluation of dosage regimen based on achieved serum concentrations in neonates.Antimicrobial agents and chemotherapy · 2025Article
- Impact of Dual Antibiotic Prophylaxis on 90-Day Surgical Site Infection Rates Following Posterior Spinal Fusion for Juvenile Scoliosis: A Single-Center Study of 296 Cases.Medicina (Kaunas, Lithuania) · 2025Review
- Amikacin dosing in neonates: evaluation of target attainment using a simplified and complex pharmacokinetic model-derived dosing regimen in clinical practice.Antimicrobial agents and chemotherapy · 2025Article
- A Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants.Clinical pharmacokinetics · 2025Review
- Predictive Performance of Population Pharmacokinetic Models for Amikacin in Term Neonates.Paediatric drugs · 2023Article
- Does "Birth" as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full-Term Neonates by Avoiding the Creatinine Bias.Journal of clinical pharmacology · 2021Article
- Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis.Antimicrobial agents and chemotherapy · 2018Article
- Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses.Clinical pharmacokinetics · 2018Review
- Amikacin: Uses, Resistance, and Prospects for Inhibition.Molecules (Basel, Switzerland) · 2017Review
- Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children.Clinical pharmacokinetics · 2015Review
- Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice.Antimicrobial agents and chemotherapy · 2015Article
- Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.Advanced drug delivery reviews · 2014Review
- Population pharmacokinetic analysis during the first 2 years of life: an overview.Clinical pharmacokinetics · 2012Review
- Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants.Antimicrobial agents and chemotherapy · 2012Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo examine the pharmacokinetics of amikacin and its pharmacokinetic pharmacodynamic (PKPD) relationship in neonates. To develop an alternative dosing strategy for amikacin in neonates.
methodsA population PKPD analysis was performed using data collected from 80 neonates with gestational ages from 24 to 41 weeks. The final pharmacokinetic model analysed 358 amikacin concentrations. All neonates were > 72 hours postnatal age. Simulations were performed to develop a new dosing strategy.
resultsThe final covariate model was clearance = 0.23 x (current weight/2)(0.691) x (postmenstrual age/40)(3.23) and volume of distribution = 0.957 x (current weight/2)(0.89). Following the logistic regression analysis of treatment failure, new amikacin target concentrations were estimated and used in development of an alternative dosing strategy.
conclusionSimulation of a new dosing regimen yielded the following recommendations: 15 mg/kg at 36-h intervals, 14 mg/kg at 24-h intervals and 15 mg/kg at 24-h intervals for neonates < or = 28 weeks, 29-36 weeks and > or = 37 weeks postmenstrual age respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.